GLP-1RA Medications And Alopecia: Evaluating Risk Across Diabetic And Non-Diabetic Populations

July 2026 in “ Journal of the American Academy of Dermatology ”

Adam He, Harrison Zhu, Anna Catinis … Chad Housewright

glucagon-like peptide-1 receptor agonist GLP-1RA alopecia type 2 diabetes mellitus T2DM BMI

Studysummary GLP-1RA medications may increase the risk of hair loss, especially in non-diabetic people.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer ·

Read the full study on jaad.org →

Discuss this study in the Community →

Similar research 5

Supplementary Material for: GLP-1 Receptor Agonists and Alopecia: A Systematic Review and Meta-Analysis of Incidence, Risk, Subtypes, and Mechanisms Figshare · 2026
Supplementary Material for: GLP-1 Receptor Agonists and Alopecia: A Systematic Review and Meta-Analysis of Incidence, Risk, Subtypes, and Mechanisms Figshare · 2026
GLP-1 Receptor Agonists and Alopecia: A Systematic Review and Meta-Analysis of Incidence, Risk, Subtypes, and Mechanisms Skin Appendage Disorders · 2026
Increased Incidence and Risk of Hair Loss with Glucagon-Like Peptide 1 Receptor Agonists: A Real-World Multicenter Cohort Study EMJ Dermatology · 2025
The Role of Glucagon-Like Peptide-1 Receptor Agonists in Hair Loss: Clinical Evidence and Proposed Mechanisms Dermatologic Surgery · 2026

Related Community Posts Join

6 / 1000+ results

community Positive Hair Result in Patient using Tirzepatide

4 upvotes 1 year ago

A 57-year-old man with male pattern hair loss and insulin resistance experienced hair regrowth and weight loss after using tirzepatide, without other hair treatments. Dysregulated glucose metabolism is linked to hair loss, with tirzepatide potentially improving hair density by normalizing insulin resistance.

community TDM-105795 phase 2 results are in!

27 upvotes 2 years ago

TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.

community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

133 upvotes 2 years ago

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

community Targeting multiple AGA mechanisms with commonly available substances

4 upvotes 7 years ago

The conversation discusses using a multimodal approach to treat androgenic alopecia, including substances like gamma-linolenic acid, DHA, sulforaphane, melatonin, cetirizine, astaxanthin, fisetin, apigenin, curcumin, limonene, genistein, and berberine. Users also mention using ketoconazole, minoxidil, and low-level laser therapy (LLLT) as part of their hair loss treatment regimens.

community Topical Tacrolimus For Androgenetic Alopecia (AGA)

6 upvotes 6 days ago

Topical tacrolimus is being considered for androgenetic alopecia, though its effectiveness is unproven. Other treatments mentioned include minoxidil, dutasteride, cyclosporine, and teicoplanin, with discussions on blocking the prolactin receptor for hair growth.

community Anyone with high glucose, insulin resistance, pre-diabetes or diabetes notice any regrowth after starting treatment?

5 upvotes 1 year ago

A 21-year-old male with advanced hair loss (NW7) started using finasteride and minoxidil 10 months ago but hasn't seen much progress. He is pre-diabetic with stage 1 hypertension and is seeking insights on whether treating these conditions could improve hair regrowth.